J
Jun Zhou
Researcher at Agency for Science, Technology and Research
Publications - 298
Citations - 5891
Jun Zhou is an academic researcher from Agency for Science, Technology and Research. The author has contributed to research in topics: Chemistry & Computer science. The author has an hindex of 32, co-authored 200 publications receiving 3384 citations. Previous affiliations of Jun Zhou include University of Electronic Science and Technology of China & Chongqing University.
Papers
More filters
Journal ArticleDOI
Engineering of a Nanosized Biocatalyst for Combined Tumor Starvation and Low-Temperature Photothermal Therapy
Jun Zhou,Menghuan Li,Yanhua Hou,Zhong Luo,Qiufang Chen,Hexu Cao,Runlan Huo,Chencheng Xue,Linawati Sutrisno,Lan Hao,Yang Cao,Haitao Ran,Lu Lu,Ke Li,Kaiyong Cai +14 more
TL;DR: A tumor-targeted redox-responsive composite biocatalyst is designed and fabricated, which may combine tumor starvation therapy and low-temperature photothermal therapy for the treatment of oxygen-deprived tumors.
Journal ArticleDOI
Chemically Exfoliated VSe2 Monolayers with Room-Temperature Ferromagnetism.
Wei Yu,Jing Li,Tun Seng Herng,Zishen Wang,Xiaoxu Zhao,Xiao Chi,Wei Fu,Ibrahim Abdelwahab,Jun Zhou,Jiadong Dan,Zhongxin Chen,Zhi Chen,Zejun Li,Jiong Lu,Stephen J. Pennycook,Yuan Ping Feng,Jun Ding,Kian Ping Loh +17 more
TL;DR: Using an electrochemical exfoliation approach with organic cations as the intercalants, monolayer 1T-VSe2 flakes are successfully obtained from the bulk crystal at high yield and density functional theory (DFT) calculations show that such effect can be minimized by physisorbed oxygen molecules or covalently bound thiol molecules.
Journal ArticleDOI
Hollow mesoporous silica nanoparticles facilitated drug delivery via cascade pH stimuli in tumor microenvironment for tumor therapy
TL;DR: The in vivo results demonstrated that drug loaded HMSNs significantly inhibited tumor growth while only with minimal toxic side effects, providing new insight into the development of new generation of drug delivery carriers triggering by tumor microenvironment.
Journal ArticleDOI
Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO3 nanoformulation triggers ferroptosis in target tumor cells.
Chencheng Xue,Menghuan Li,Yang Zhao,Jun Zhou,Yan Hu,Kaiyong Cai,Yanli Zhao,Shu-Hong Yu,Zhong Luo +8 more
TL;DR: An amorphous calcium carbonate (ACC)–based nanoassembly for tumor-targeted ferroptosis therapy, in which the totally degradable ACC substrate could synergize with the therapeutic interaction between doxorubicin (DOX) and Fe2+.
Journal ArticleDOI
Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo
Junjie Liu,Beilu Zhang,Zhong Luo,Xingwei Ding,Jinghua Li,Liangliang Dai,Jun Zhou,Xiaojing Zhao,Jingya Ye,Kaiyong Cai +9 more
TL;DR: In vitro tests proved that the anticancer drug loading system could efficiently induce cell apoptosis in vitro, and in vivo tumor experiments confirmed that the anti-tumor loading system can efficiently inhibit tumor growth with minimal side effects.